vasoactive-intestinal-peptide has been researched along with Acute-Kidney-Injury* in 5 studies
3 review(s) available for vasoactive-intestinal-peptide and Acute-Kidney-Injury
Article | Year |
---|---|
Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP.
Topics: Acute Kidney Injury; Amino Acid Sequence; Animals; Asthma; Atrial Natriuretic Factor; Bronchodilator Agents; Heart Failure; Humans; Lung; Molecular Sequence Data; Neuropeptides; Peptide Fragments; Pituitary Adenylate Cyclase-Activating Polypeptide; Vasoactive Intestinal Peptide; Vasodilator Agents | 1996 |
Vasoactive intestinal polypeptide.
Topics: Acute Kidney Injury; Adenoma, Islet Cell; Animals; Bicarbonates; Brain; Dehydration; Digestive System; Gastrointestinal Hormones; Hormones, Ectopic; Humans; Nerve Fibers; Neurotransmitter Agents; Pancreas; Pancreatic Neoplasms; Swine; Syndrome; Vasoactive Intestinal Peptide | 1980 |
[Hormones of the digestive system. II. Pathology].
Topics: Acute Kidney Injury; Adenoma, Islet Cell; Adolescent; Adult; Aged; Carcinoid Tumor; Child; Dehydration; Female; Gastric Inhibitory Polypeptide; Gastrins; Gastrointestinal Hormones; Gastrointestinal Neoplasms; Glucagon; Humans; Hyperplasia; Hypokalemia; Insulin; Insulin Secretion; Male; Middle Aged; Pancreatic Neoplasms; Paraneoplastic Endocrine Syndromes; Precancerous Conditions; Serotonin; Somatostatin; Syndrome; Vasoactive Intestinal Peptide; Zollinger-Ellison Syndrome | 1978 |
2 other study(ies) available for vasoactive-intestinal-peptide and Acute-Kidney-Injury
Article | Year |
---|---|
Verner-Morrison syndrome and vasoactive intestinal polypeptide (VIP).
The clinical features of the Verner-Morrison syndrome are surveyed. This rare clinical entity still needs to be more clearly defined. Especially in relation to the role of VIP and the clinical value of VIP measurements. A case with a good correlation between the activity of the disease and circulating VIP is presented. Topics: Acute Kidney Injury; Adenoma, Islet Cell; Dehydration; Gastrointestinal Hormones; Humans; Pancreatic Neoplasms; Radioimmunoassay; Streptozocin; Syndrome; Vasoactive Intestinal Peptide | 1979 |
Streptozotocin treatment of a pancreatic tumour producing VIP and gastrin associated with Verner-Morrison syndrome.
A 57-year-old male patient with metastasizing non-beta islet cell carcinoma of the pancreas is described. Both gastrin and VIP levels were elevated and the patient suffered from a syndrome of pancreatic cholera and hyperacidity. The tumour contained gastrin and VIP as demonstrated by immunofluorescence. The patient also had a history of familial renal stone formation and parathyroid nodular hyperplasia. Resection of pancreatic tumour in 1973 resulted in four years without symptoms. In 1977 definite signs of multiple hepatic metastases appeared. These signs disappeared after streptozotocin given in a dosage of 2 g three times at weekly intervals. The patient had remained well for 20 months after this treatment. The causative agents for the clinical syndrome in this case are discussed in view of circulating hormone levels. Topics: Acute Kidney Injury; Adenoma, Islet Cell; Dehydration; Gastrins; Gastrointestinal Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pancreatic Polypeptide; Streptozocin; Syndrome; Vasoactive Intestinal Peptide | 1979 |